PEDIATRICS Vol. 115 No. 1 January 2005, pp. 198 (doi:10.1542/peds.2004-2355)
Delivery Room Continuous Positive Airway Pressure: Practice and Feasibility: In Reply
Neil N. Finer, MDDepartment of Pediatrics,
University of California,
San Diego, CA 92103-8774
Waldemar A. Carlo, MD
Department of Pediatrics,
University of Alabama,
Birmingham, AL 35294
Shahnaz Duara, MD
Department of Pediatrics,
University of Miami,
Miami, FL 33136
Edward F. Donovan, MD
Department of Pediatrics,
College of Medicine,
University of Cincinnati,
Cincinnati, OH 45221
Avroy A. Fanaroff, MB, BCh
Department of Pediatrics,
Case Western Reserve University,
Cleveland, OH 44106
We thank Hand and Noble for their comments and agree that there is a definite learning curve with the introduction of any new technology. We are about to begin the SUPPORT trial, which will compare the use of early continuous positive airway pressure (CPAP) and a permissive ventilator strategy started at delivery and early surfactant followed by conventional ventilation, similar to the COIN trial, in infants of 24 to 27 6/7 weeks' gestation. In addition, the infants will be randomized to 2 target ranges of oxygen saturation (85% to 89% and 91% to 95%), starting within 2 hours of birth.
We believe that it is important not to encourage the dissemination of any new form of therapy for preterm infants until it has been demonstrated to be efficacious and safe without compromising longer-term neurodevelopmental outcome, lest we repeat mistakes from our past.1 Sandri et al2 recently reported that there is no advantage of early/prophylactic CPAP compared with later rescue CPAP for infants of 28 to 31 weeks' gestation in terms of the need for later intubation surfactant and ventilation. The most optimal use of CPAP in the very low birth weight infant has yet to be determined.
The use of CPAP predated surfactant in neonatal medicine, and although both have been available for at least 10 years, there has not been a well-designed and powered prospective trial comparing these 2 therapies. We believe that additional prospective randomized trials such as the COIN Trial, the Vermont Oxford Network trial, and the SUPPORT trial will provide additional evidence for the potential benefit of CPAP compared with early surfactant in such infants. There are many forks in the road to evidence-based neonatal care, and, following the advice of Yogi Berra, we need to "take them" to their logical conclusion.
REFERENCES
1. American Academy of Pediatrics, Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.
Pediatrics. 2002;109
:330
338
2. Sandri F, Ancora G, Lanzoni A, et al. Prophylactic nasal continuous positive airways pressure in newborns of 2831 weeks gestation: multicentre randomised controlled clinical trial.
Arch Dis Child Fetal Neonatal Ed. 2004;89
:F394
F398
PEDIATRICS (ISSN 1098-4275). ©2005 by the American Academy of Pediatrics
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





